Skip to content
Open in App
Abcellera Biologics logo

Abcellera Biologics

web2

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for ind...

Symbol · ABCL
Company profile

About

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ABCL
Expert coverage

1 expert evaluated Abcellera Biologics.

Orbitrum research

Experts evaluating Abcellera Biologics

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment